Association between time to treatment and outcome in branch retinal vein occlusion
Author:
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1007/s10792-024-03272-w.pdf
Reference28 articles.
1. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY (2010) International eye disease consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(2):313–319. https://doi.org/10.1016/j.ophtha.2009.07.017
2. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, Nguyen HP, Wang JJ, Wong TY (2010) Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6):1113–1123. https://doi.org/10.1016/j.ophtha.2010.01.058
3. David G, Bobby T, Caroline B, Andrea R (2023) Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion. Int Ophthalmol 43(11):4105–4110. https://doi.org/10.1007/s10792-023-02811-1
4. Francesco P, Ahmed ME, Tarek RE (2019) Outcome of “treat and monitor” regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion. Int Ophthalmol 39(1):145–153. https://doi.org/10.1007/s10792-017-0798-6
5. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A; RETAIN Study Group (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 121:209–219. https://doi.org/10.1016/j.ophtha.2013.08.038
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3